VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

Stock Information for VolitionRX Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About VolitionRX Limited

Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
Volition Sponsors Symposium at Veterinary Meeting and Expo
VolitionRx Secures $2.0 Million in Funding
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
Volition Issues Business Review 2025
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.